건선 치료제 시장 규모, 점유율, 예측, 동향 분석, 치료별, 질환별 - 세계 예측(-2031년)

Psoriasis Treatment Market Size, Share, Forecast, & Trends Analysis by Treatment (TNF Inhibitor, Interleukin, Corticosteroids, Calcitrol, Retinoids, Calcineurin, Methotrexate) Disease (Plaque Psoriasis, Psoriatic Arthritis) - Global Forecast to 2031

US $ 4,175 ￦ 6,194,000

PDF & Excel (Single User License)

PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 파일 내 텍스트 등의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF·Excel 이용 범위와 동일합니다.

US $ 5,875 ￦ 8,716,000

PDF & Excel (Multi User License)

PDF & Excel 보고서를 동일 기업내 5명까지 이용할 수 있는 라이선스입니다. 파일 내 텍스트 등의 Copy & Paste 가능합니다. 5부까지 인쇄 가능하며 인쇄물의 이용 범위는 PDF·Excel 이용 범위와 동일합니다.

US $ 7,875 ￦ 11,684,000

PDF & Excel (Global Site License)

PDF & Excel 보고서를 동일 기업 & 자회사의 모든 분이 이용할 수 있는 라이선스입니다. 파일 내 텍스트 등의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF·Excel 이용 범위와 동일합니다.

한글목차

건선 치료제 시장은 2024-2031년간 연평균 복합 성장률(CAGR) 9.8%로 성장하여 2031년 350억 7,000만 달러에 달할 것으로 예상됩니다.

이 보고서는 철저한 2차 및 1차 조사, 시장 시나리오에 대한 심층 분석을 바탕으로 주요 시장 성장 촉진요인, 과제, 기회 및 동향에 대해 논의합니다.

이 시장의 성장은 건선의 높은 부담, 치료 옵션 및 진단 방법의 발전, 질병 발병에 대한 더 나은 이해, 고령화 인구의 건선 유병률 증가 등의 요인에 의해 주도될 것으로 예상됩니다. 또한, 건선에 대한 인식 증가, 병용요법 사용률 증가, 건선에 대한 연구 진행은 시장 성장의 기회를 창출할 것으로 예상됩니다.

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 시장 인사이트

• 개요
• 성장 촉진요인
• 성장 억제요인
• 기회
• 과제
• 동향
• 요인 분석
• 제품 파이프라인 분석
• 규제 분석
• Porter의 Five Forces 분석
• 자금조달과 투자 분석

제5장 건선 치료 시장 : 검사 유형별 평가

• 개요
• 생물학적 제제
  • TNF 억제제
    • Infliximab
    • Adalimumab
    • Etanercept
    • 기타 TNF 억제제
  • 인터류킨 억제제
    • Guselkumab
    • Risankizumab
    • Tildrakizumab
  • 기타 생물학적 제제
• 국소 치료제
  • 부신 피질 스테로이드
    • Hydrocortisone
    • Desonide
    • Betamethasone
    • 기타 부신피질 스테로이드
  • 비타민 D 아날로그
    • Calcitrol
    • Calcipotriol
    • Tacalcitol
  • 레티노이드
  • 칼시뉴린 억제제
• 전신 치료제
  • Methotrexate
  • Cyclosporine
  • Acitretin
  • 기타 전신 치료제

제6장 건선 치료 시장 : 질환 유형별 평가

• 개요
• 플라크 건선
• 건선성 관절염
• 기타 유형

제7장 건선 치료 시장 : 투여 경로별 평가

• 개요
• 경구제
• 국소
• 주사제

제8장 건선 치료 시장 : 유통 채널별 평가

• 개요
• 병원 약국
• 소매 약국
• 온라인/E-Commerce 플랫폼

제9장 건선 치료 시장 : 지역별 평가

• 개요
• 북미
  • 미국
  • 캐나다
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 네덜란드
  • 스위스
  • 폴란드
  • 기타 유럽
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • 호주
  • 뉴질랜드
  • 기타 아시아태평양
• 라틴아메리카
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
• 중동 및 아프리카

제10장 경쟁 분석

• 개요
• 주요 성장 전략
• 경쟁 벤치마킹
• 경쟁 대시보드
  • 업계 리더
  • 시장 차별화 요인
  • 선행 기업
  • 신규 기업
• 주요 기업별 시장 점유율 분석/시장 순위 분석(2023년)

제11장 기업 개요(사업 개요, 재무 개요, 제품 포트폴리오, 전략적 전개, SWOT 분석*).

• AbbVie Inc.(U.S.)
• AstraZenca Plc(U.K.)
• Boehringer Ingelheim(Germany)
• Celgene Corporation(U.S.)
• Eli Lilly and Company(U.S.)
• Johnson and Johnson(U.S.)
• Merck KGaA(Germany)
• Novartis AG(Switzerland)
• Pfizer Inc.(U.S.)
• Takeda Pharmaceutical Company Limited(Japan)
• Biogen, Inc.(U.S.)
• LEO Pharma A/S(Denmark)
• Sun Pharmaceutical Industries Ltd.(India)
• Dr. Reddy's Laboratories Ltd.(India)

(주 : 주요 5개사의 SWOT 분석을 제공 예정)

제12장 부록

LSH

영문 목차

영문목차

Psoriasis Treatment Market Size, Share, Forecast, & Trends Analysis By Treatment (TNF Inhibitor, Interleukin, Corticosteroids, Calcitriol, Retinoids, Calcineurin, Methotrexate) Disease (Plaque Psoriasis, Psoriatic Arthritis) - Global Forecast to 2031

The psoriasis treatment market is expected to reach $35.07 billion by 2031, at a CAGR of 9.8% from 2024 to 2031.

Following thorough secondary and primary research and in-depth analysis of the market scenario, the report discusses key industry drivers, restraints, challenges, opportunities, and trends.

The growth of this market is driven by factors such as the high burden of psoriasis, advancements in treatment options & diagnosis methods, a better understanding of disease pathogenesis, and the rising prevalence of psoriasis among the aging population. Additionally, increasing awareness of psoriasis, the rising utilization of combination therapies, and ongoing research on psoriasis are expected to create market growth opportunities.

Based on treatment type, the market is segmented into biologic drugs, topical treatments, and systemic treatments. The biologics drugs segment is projected to witness the highest growth rate of 7.4% during the forecast period of 2024-2031. The growth of this segment is driven by the increasing adoption of Interleukin inhibitors over conventional systemic medications due to their enhanced effectiveness and improved safety profile. Additionally, ongoing advancements in biologic drugs and initiatives by market players to introduce new biologic treatments for psoriasis are contributing to the segment's growth. For instance, in March 2023, Eli Lilly and Company (U.S.) launched Copellor, an interleukin inhibitor specifically designed for treating psoriasis, in India.

Based on disease type, the psoriasis treatment market is segmented into plaque psoriasis, psoriatic arthritis, and others. The psoriatic arthritis segment is expected to record the highest CAGR during the forecast period of 2024-2031. This segment's growth is driven by the increasing prevalence of psoriatic arthritis among patients with plaque psoriasis, growing awareness about the condition, and advancements in treatment for managing the disease.

Based on administration route, the global psoriasis treatment market is segmented into oral, topical, and injectable. The injectable segment is projected to register the highest CAGR during the forecast period of 2024-2031. This segment is driven by the increasing adoption of biologic therapies, which are mainly administered via injections, advancements in injection technology such as prefilled syringes and autoinjectors, and the increasing availability and accessibility of injectable medications through various distribution channels, including specialty pharmacies and online platforms.

Based on distribution channel, the global psoriasis treatment market is segmented into hospital pharmacies, retail pharmacies, and online/e-commerce platforms. The online/e-commerce platforms segment is expected to register the highest CAGR during the forecast period. This growth can be attributed to the proliferation of e-commerce platforms, the rapid pace of digitalization, and the convenience of online shopping. These platforms provide a wide range of products, enabling patients to easily compare prices, read reviews, and access information about various treatment options.

An in-depth analysis of the geographical scenario of the psoriasis treatment market provides detailed qualitative and quantitative insights into five major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of the global psoriasis treatment market, followed by Europe and Asia-Pacific. North America's significant market share can be attributed to the high prevalence of psoriasis, widespread adoption of personalized therapies, advanced health infrastructure, and ongoing research and development efforts focused on psoriasis. These efforts have resulted in new treatment approaches and drugs being continuously developed and introduced to the market.

Key companies operating in the global psoriasis treatment market are AbbVie Inc. (U.S.), AstraZenca Plc (U.K.), Boehringer Ingelheim (Germany), Celgene Corporation (U.S.), Eli Lilly and Company (U.S.), Johnson and Johnson (U.S.), Merck KGaA (Germany), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), Biogen, Inc. (U.S.), LEO Pharma A/S (Denmark), Sun Pharmaceutical Industries Ltd. (India), and Dr. Reddy's Laboratories Ltd. (India).

Scope of the Report:

Psoriasis Treatment Market Assessment-by Treatment Type

• Biologic Drugs
  • TNF Inhibitors
• Infliximab
• Adalimumab
• Etanercept
• Other TNF Inhibitors
  • Interleukin Inhibitors
• Guselkumab
• Risankizumab
• Tildrakizumab
  • Other Biologic Drugs (Anakinra, Basiliximab, Daclizumab, and Briakinumab, among others)
• Topical Treatments
  • Corticosteroids
• Hydrocortisone
• Desonide
• Betamethasone
• Other Corticosteroids
  • Vitamin D Analogs
• Calcitriol
• Calcipotriol
• Tacalcitol
  • Retinoids
  • Calcineurin Inhibitors
• Systemic Treatments
  • Methotrexate
  • Cyclosporine
  • Acitretin
  • Other Systemic Drugs (Apremilast, Cyclosporine, Adalimumab, Ustekinumab, Etanercept, Tofacitinib, and Tildrakizumab, among others)

Psoriasis Treatment Market Assessment-by Disease Type

• Plaque Psoriasis
• Psoriatic Arthritis
• Other Psoriasis Types (Guttate Psoriasis, Pustular Psoriasis, Inverse Psoriasis, and Erythrodermic Psoriasis)

Psoriasis Treatment Market Assessment-by Administration Route

• Oral
• Topical
• Injectable

Psoriasis Treatment Market Assessment-by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online/E-commerce Platforms

Psoriasis Treatment Market Assessment-by Geography

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Netherlands
  • Switzerland
  • Poland
  • Rest of Europe (RoE)
• Asia-Pacific (APAC)
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • Rest of Asia-Pacific (RoAPAC)
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America (RoLATAM)
• Middle East & Africa

TABLE OF CONTENTS

1. Overview

• 1.1. Market Definition & Scope
• 1.2. Market Ecosystem
• 1.3. Currency and Limitations
• 1.4. Key Stakeholders

2. Research Methodology

• 2.1. Research Approach
• 2.2. Process of Data Collection & Validation
  • 2.2.1. Secondary Research
  • 2.2.2. Primary Research/Interviews with Key Opinion Leaders of The Industry
• 2.3. Market Sizing and Forecast
  • 2.3.1. Market Size Estimation Approach
  • 2.3.2. Growth Forecast Approach
  • 2.3.3. Market Share Analysis
• 2.4. Assumptions For the Study

3. Executive Summary

4. Market Insights

• 4.1. Overview
• 4.2. Factors Affecting Market Growth
  • 4.2.1. Drivers
    • 4.2.1.1. High Burden of Psoriasis
    • 4.2.1.2. Advancements in Treatment Options
    • 4.2.1.3. Improved Psoriasis Diagnosis
    • 4.2.1.4. Elderly People More Susceptible to Psoriasis
  • 4.2.2. Restraints
    • 4.2.2.1. High Costs of Psoriasis Treatments
    • 4.2.2.2. Side Effects of Medications
  • 4.2.3. Opportunities
    • 4.2.3.1. Rising Awareness Regarding Psoriasis
    • 4.2.3.2. Growing Use of Combination Therapies for Treatment
    • 4.2.3.3. Growing Research Regarding Psoriasis
  • 4.2.4. Challenges
    • 4.2.4.1. Stringent Regulatory & Approval Process of Drugs
• 4.3. Trends
  • 4.3.1. Targeted Therapies
  • 4.3.2. Steroid-free Topicals
• 4.4. Factor Analysis
• 4.5. Product Pipeline Analysis
• 4.6. Regulatory Analysis
• 4.7. Porter's Five Forces Analysis
• 4.8. Fundings & Investments Analysis

5. Psoriasis Treatment Market Assessment-by Test Type

• 5.1. Overview
• 5.2. Biologic Drugs
  • 5.2.1. TNF Inhibitors
    • 5.2.1.1. Infliximab
    • 5.2.1.2. Adalimumab
    • 5.2.1.3. Etanercept
    • 5.2.1.4. Other TNF Inhibitors
  • 5.2.2. Interleukin Inhibitors
    • 5.2.2.1. Guselkumab
    • 5.2.2.2. Risankizumab
    • 5.2.2.3. Tildrakizumab
  • 5.2.3. Other Biologic Drugs
• 5.3. Topical Treatments
  • 5.3.1. Corticosteroids
    • 5.3.1.1. Hydrocortisone
    • 5.3.1.2. Desonide
    • 5.3.1.3. Betamethasone
    • 5.3.1.4. Other Corticosteroids
  • 5.3.2. Vitamin D Analogs
    • 5.3.2.1. Calcitrol
    • 5.3.2.2. Calcipotriol
    • 5.3.2.3. Tacalcitol
  • 5.3.3. Retinoids
  • 5.3.4. Calcineurin Inhibitors
• 5.4. Systemic Treatments
  • 5.4.1. Methotrexate
  • 5.4.2. Cyclosporine
  • 5.4.3. Acitretin
  • 5.4.4. Other Systemic Treatments

6. Psoriasis Treatment Market Assessment-by Disease Type

• 6.1. Overview
• 6.2. Plaque Psoriasis
• 6.3. Psoriatic Arthritis
• 6.4. Other Types

7. Psoriasis Treatment Market Assessment-by Administration Route

• 7.1. Overview
• 7.2. Oral
• 7.3. Topical
• 7.4. Injectable

8. Psoriasis Treatment Market Assessment- by Distribution Channel

• 8.1. Overview
• 8.2. Hospital Pharmacies
• 8.3. Retail Pharmacies
• 8.4. Online/E-commerce Platforms

9. Psoriasis Treatment Market Assessment-by Geography

• 9.1. Overview
• 9.2. North America
  • 9.2.1. U.S.
  • 9.2.2. Canada
• 9.3. Europe
  • 9.3.1. Germany
  • 9.3.2. France
  • 9.3.3. U.K.
  • 9.3.4. Italy
  • 9.3.5. Spain
  • 9.3.6. Netherlands
  • 9.3.7. Switzerland
  • 9.3.8. Poland
  • 9.3.9. Rest of Europe
• 9.4. Asia-Pacific
  • 9.4.1. China
  • 9.4.2. India
  • 9.4.3. Japan
  • 9.4.4. Australia
  • 9.4.5. New Zealand
  • 9.4.6. Rest of Asia-Pacific
• 9.5. Latin America
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America
• 9.6. Middle East & Africa

10. Competition Analysis

• 10.1. Overview
• 10.2. Key Growth Strategies
• 10.3. Competitive Benchmarking
• 10.4. Competitive Dashboard
  • 10.4.1. Industry Leaders
  • 10.4.2. Market Differentiators
  • 10.4.3. Vanguards
  • 10.4.4. Emerging Companies
• 10.5. Market Share Analysis/ Market Ranking Analysis, by Key Players (2023)

11. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis*)

• 11.1. AbbVie Inc. (U.S.)
• 11.2. AstraZenca Plc (U.K.)
• 11.3. Boehringer Ingelheim (Germany)
• 11.4. Celgene Corporation (U.S.)
• 11.5. Eli Lilly and Company (U.S.)
• 11.6. Johnson and Johnson (U.S.)
• 11.7. Merck KGaA (Germany)
• 11.8. Novartis AG (Switzerland)
• 11.9. Pfizer Inc. (U.S.)
• 11.10. Takeda Pharmaceutical Company Limited (Japan)
• 11.11. Biogen, Inc. (U.S.)
• 11.12. LEO Pharma A/S (Denmark)
• 11.13. Sun Pharmaceutical Industries Ltd. (India)
• 11.14. Dr. Reddy's Laboratories Ltd. (India)

(Note: SWOT Analysis of the Top 5 Companies Will Be Provided)

12. Appendix

• 12.1. Available Customization
• 12.2. Related Reports

관련자료